The theory incorporates high incidence and burden of leukemia, higher frequency classic and novel adverse biologic features (such as iAMP21, t(1;19)/EA2-PBX1, CRLF2, TPMT, and NUDT15 mutations), and suboptimal treatment among Mexican and Hispanic children to explain the poor outcomes. This evidence concerns the gene PBX1 and leukemia.